Oncocross Co., Ltd. (KOSDAQ:382150)
South Korea · Delayed Price · Currency is KRW 7,750.00
+550.00 (7.64%)
Apr 3, 2026, 3:30 PM KST
Oncocross Revenue
In the year 2025, Oncocross had annual revenue of 370.46M KRW, down -65.45%. Oncocross had revenue of 140.93M in the quarter ending December 31, 2025, a decrease of -78.49%.
Revenue
370.46M
Revenue Growth
-65.45%
P/S Ratio
255.14
Revenue / Employee
n/a
Employees
n/a
Market Cap
94.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 370.46M | -701.74M | -65.45% |
| Dec 31, 2024 | 1.07B | 980.68M | 1,071.49% |
| Dec 31, 2023 | 91.52M | -58.72M | -39.08% |
| Dec 31, 2022 | 150.25M | 50.25M | 50.25% |
| Dec 31, 2021 | 100.00M | 10.00M | 11.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Macrogen | 179.98B |
| Amicogen | 87.97B |
| ORIENT BIO | 59.09B |
| GeneOne Life Science | 30.90B |
| CG Invites | 27.39B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |
| IMB Dx | 5.33B |